Back to top
more

Immunocore (IMCR)

(Delayed Data from NSDQ)

$32.53 USD

32.53
178,780

-0.46 (-1.39%)

Updated Aug 4, 2025 03:59 PM ET

After-Market: $32.56 +0.03 (0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) closed the most recent trading day at $57.61, moving -1.69% from the previous trading session.

Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) closed the most recent trading day at $64.51, moving +1.9% from the previous trading session.

Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) Surges 6.5%: Is This an Indication of Further Gains?

by Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) closed at $61.26 in the latest trading session, marking a -1.62% move from the prior day.

Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) closed the most recent trading day at $63.52, moving +1.78% from the previous trading session.

Zacks Equity Research

Here is What to Know Beyond Why Immunocore Holdings PLC Sponsored ADR (IMCR) is a Trending Stock

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Immunocore Holdings PLC Sponsored ADR (IMCR). This makes it worthwhile to examine what the stock has in store.

Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) closed the most recent trading day at $60.69, moving +0.03% from the previous trading session.

Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Immunocore Holdings PLC Sponsored ADR (IMCR) closed at $59.62, marking a -0.53% move from the previous day.

Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) closed the most recent trading day at $59.13, moving -1.58% from the previous trading session.

Zacks Equity Research

Is Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Immunocore Holdings PLC Sponsored ADR (IMCR) and Allogene Therapeutics (ALLO) have performed compared to their sector so far this year.

Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) Soars 6.9%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Heska (HSKA) Moves 9.0% Higher: Will This Strength Last?

by Zacks Equity Research

Heska (HSKA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Exelixis (EXEL) Announces Preliminary Q4 and 2022 Results

by Zacks Equity Research

Exelixis (EXEL) reports preliminary revenues for the fourth quarter and 2022. It also provides guidance for 2023 and pipeline updates.

Zacks Equity Research

FATE To End Janssen Deal and Prioritize Pipeline Development

by Zacks Equity Research

FATE decides not to continue its collaboration and option agreement with Janssen. The company also conducts a strategic review.

Zacks Equity Research

Phathom (PHAT) Down on Regulatory Update on Vonoprazan NDA

by Zacks Equity Research

Phathom Pharmaceuticals, Inc. (PHAT) declines as the FDA decides to not take any action on Phathom's new drug application (NDA) for vonoprazan for treating erosive esophagitis.

Zacks Equity Research

Best Momentum Stocks to Buy for December 30th

by Zacks Equity Research

IMCR, RGA and VCISY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 30, 2022.

Zacks Equity Research

New Strong Buy Stocks for December 30th

by Zacks Equity Research

IMCR, RGA, LPLA, ACR and VCISY have been added to the Zacks Rank #1 (Strong Buy) List on December 30, 2022.

Zacks Equity Research

Kala Pharmaceuticals (KALA) Up as FDA Accepts IND for KPI-012

by Zacks Equity Research

The FDA accepts Kala Pharmaceuticals' (KALA) investigational new drug application for pipeline candidate KPI-012 for treating persistent corneal epithelial defect. Stock up.

Zacks Equity Research

ACER Down Despite FDA Nod for Urea Cycle Disorders Drug

by Zacks Equity Research

The FDA approves Acer Therapeutics' (ACER) Olpruva (sodium phenylbutyrate) to treat certain patients with urea cycle disorders. Share price falls 33.3% following the announcement.

Zacks Equity Research

Zacks Industry Outlook Highlights Gilead Sciences, GSK, Immunocore and Syndax Pharmaceuticals

by Zacks Equity Research

Gilead Sciences, GSK, Immunocore and Syndax Pharmaceuticals are part of the Zacks Screen of the Week article.

Zacks Equity Research

4 Top Biotech Stocks Worth Adding to Your Portfolio in 2023

by Zacks Equity Research

New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, GSK, IMCR and SNDX well amid the volatility.

Zacks Equity Research

DBV (DBVT) Up as FDA Lifts Partial Hold on Peanut Allergy Study

by Zacks Equity Research

The FDA lifts the partial clinical hold on DBV Technologies' (DVBT) phase III VITESSE study of a modified Viaskin Peanut patch in peanut-allergic children aged four to seven years. Stock rises.

Zacks Equity Research

ProQR (PRQR) Rises on Expanding RNA-Editing Deal With Eli Lilly

by Zacks Equity Research

ProQR (PRQR) expands its existing licensing and collaboration agreement with Eli Lilly for the discovery, development and commercialization of new genetic medicines.

Zacks Equity Research

ORIC Rises on Team-Up With Pfizer for Multiple Myeloma Study

by Zacks Equity Research

ORIC inks a collaboration deal with Pfizer for a phase II study evaluating ORIC-533 in combination with the latter's elranatamab in multiple myeloma. Stock up in after-hours trading.

Zacks Equity Research

The Zacks Analyst Blog Highlights United Therapeutics, Intra-Cellular Therapies, Immunocore Holdings and Eli Lilly

by Zacks Equity Research

United Therapeutics, Intra-Cellular Therapies, Immunocore Holdings and Eli Lilly are part of the Zacks top Analyst Blog.